Show simple item record

dc.contributor.authorLee, Stacey
dc.date.accessioned2011-03-24T14:34:21Z
dc.date.available2011-03-24T14:34:21Z
dc.date.issued2011
dc.identifier.urihttp://jhir.library.jhu.edu/handle/1774.2/34784
dc.description.abstractIn Wyeth v. Levine, the Supreme Court eliminated brand-name manufacturers’ ability to use the preemption defense against state law failure to warn claims involving allegedly misbranded pharmaceutical drugs. Since that time, a heated debate has ensued among federal courts and legal scholars regarding that holding’s effect on generic manufacturers. Lost amid these judicial opinions and scholarly articles, however, is a more fundamental inquiry. Regardless of whether preemption is a viable defense, what type of legal and regulatory framework is needed to ensure generic manufacturers possess the necessary tools to fulfill their responsibility of providing consumers and the medical community with current and accurate labeling instructions for their products? This Article proposes such a framework.en
dc.language.isoen_USen
dc.relation.ispartofseriesTeh Johns Hopkins Carey Business school Working Paper Series;11-03-001
dc.subjectK2en
dc.subjectGenerics, Preemption, Drug Labeling Regulatory Frameworken
dc.titleGeneric Manufacturers’ Labeling Catch-22en
dc.typeWorking Paperen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record